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Abstract
Background: This study assesses the reliability and validity of the Dutch version of a disease-specific measure of health-related
quality of life (HRQOL) for adolescents and adults with CF (CFQ-14q). The 47-item CFQ-14q covers nine domains, three
symptom scales and one health perception scale. Methods: To assess psychometric characteristics of the CFQ-14q, cross-sectional
(homogeneity, discriminative and construct validity) and test–retest designs were used. Eighty-four adolescents and adults with
CF (mean age: 21.4 years, range 14.0–46.5 years) and a wide range of lung function (mean FEV : 59,9% predicted, range 15–1
121%) completed the questionnaire during a routine visit. Results: Internal consistency was acceptable for most domains of the
CFQ-14q (as0.43–0.92) and test–retest reliability was high for all domain scores (0.72–0.98). Several domains of the CFQ-
14q were able to differentiate between individuals with varying disease severity and between nourished and malnourished
patients. Construct validity of the questionnaire was fair, with moderate to strong correlation between physically orientated
domains and pulmonary function (r s0.36–0.62). Conclusion: The results demonstrate that the CFQ-14q questionnaire is as
well-validated measure of HRQOL assessment in adolescents and adults with CF.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Advances in therapy and treatment of cystic fibrosis
(CF) have led to improved patient survival into adult-
hood w1x. However, therapy and treatment of CF, coupled
with the progressive nature of the disease, which can
require hospitalization, makes management of CF time-
consuming and difficult w1,2x. Traditional clinical meas-
ures are important but they do not capture the broader
impact of the disease w3–5x. The measurement of health-
related quality of life (HRQOL) in CF provides addi-
tional information about the impact of the disease on
physical, social and psychological functioning w2,5,6x.
*Corresponding author. Tel.: q31-35688-1411; fax: q31-35688-
1499.
E-mail address: pklijn@heideheuvel.nl (P.H. Klijn).
Studies on HRQOL in patients with CF have typically
used generic or specific respiratory questionnaires which
were not specifically developed for CF w7–12x. Generic
health measures allow for comparisons between a variety
of diseases, but are not sensitive for specific problems
associated with CF w6x and may not be sufficiently
responsive to the effects of clinical interventions.
Recently, a reliable and valid CF-specific health-related
measure was developed and validated in France, the
Cystic Fibrosis Questionnaire (CFQ) w13x. In addition,
the CFQ has been validated in Germany w14x and is
presently being validated in the United States and Spain.
The CFQ consists of three quality of life measures: an
adolescentyadult version (14 years of age or older), a
child version (6–13 years of age) and a parent version
(used in conjunction with the child measure). The
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advantage of the CFQ is that it takes into account
differences in developmental stages and makes it possi-
ble to monitor the health status and quality of life in
CF patients from the age of 6 years throughout adult-
hood w6,15x. This allows health care professionals to
analyze long-term outcome and efficacy of early
intervention.
Cross-cultural validation of an existing measure has
the advantage of avoiding the initial stages of develop-
ment of a new questionnaire, which is a long process
w16,17x. Furthermore, translation into different languages
makes it possible to use the CFQ questionnaires in
comparative international multi-center studies w16x.
The aims of the present study were: (1) to develop a
conceptually equivalent Dutch version of the CFQ for
adolescents and adults with CF and (2) to evaluate the
following characteristics: homogeneity, reproducibility
(10–14 days test–retest reliability), discriminative and
construct validity.
The Dutch CFQ for children with CF and their parents
is presently being validated.
2. Methods
2.1. Patients and procedure
Eighty-four patients were recruited from the children
and adult CF-Center of the University Medical Center
Utrecht. All patients were approached during routine
visits between 2001 and 2002 and asked for consent to
complete the CFQ. Patients who had problems under-
standing the Dutch language were excluded from the
study. In a subset of clinically stable patients, as deter-
mined by a pulmonologist, the questionnaire was admin-
istered twice within 10–14 days. The study was
approved by the institutional Medical Ethics Committee.
2.2. Translation
Backward and forward translations were completed.
The French CFQ was translated into Dutch and a second
independent translator made a backward translation into
French. A third expert compared the original French list
to the backward translated French list. Discussions were
held between the translators to resolve semantic and
conceptual discrepancies and to develop a consensus
forward translation.
2.3. Cystic fibrosis questionnaire
The CFQ for adolescents and adults (CFQ-14q)
consists of 47 items divided into nine domains: physical
functioning (8 items), energy and well-being (4), emo-
tional state (5), social limitations (4), role limitations
(2), body image (3), eating disturbances (2), treatment
burden (2), and embarrassment (3). Three symptom
scales are included, respiratory (7), digestive (2), and
weight (1), and overall health perception (4). Items
require either a frequency response on a 4-point scale
(‘all the time’ to ‘never’), a difficulty rating on a 4-
point scale (‘a lot of difficulty’ to ‘no difficulty’), a
true–false rating on a 4-point scale, or the selection of
a statement that describes the patient (on a 3-or 4-point
scale) w6x. Completing the questionnaire took approxi-
mately 15 min.Scores are standardized by adding the
ratings of all items within a domain to facilitate com-
parison of scores across domains. The scores range from
0 to 100 with higher scores corresponding to higher
quality of life. Scores for each domain are calculated if
at least two-thirds of the items are completed. There is
no total score.
Appendix A outlines the distribution of the questions
by domain for CFQ-14q.
2.4. Homogeneity
Internal consistency of each domain was assessed
using Cronbach alpha coefficients (i.e. the strength of
the associations between items and their respective
domains). Generally the internal reliability is acceptable
with a Cronbach alpha coefficient of 0.7 or above w18x.
However, slightly lower coefficients (0.6 or higher) are
acceptable for newly developed scales w19x. Further-
more, item to domain correlations were calculated. These
correlations assess whether items are more strongly
associated with their hypothesized vs. competing scale.
Psychometric guidelines suggest that item to domain
correlations should be 0.40 or greater w19x.
2.5. Reproducibility
Test–retest reliability measures the stability of the
scores on the CFQ questionnaires over time. Twenty-
one patients with a stable clinical condition (i.e. no need
for oral or intravenous antibiotic treatment in 3 months
prior to testing) completed the CFQ 10–14 days apart.
This period is long enough not to introduce memory as
a confounding factor while being short enough to pre-
vent deterioration in disease status w20x.
2.6. Discriminative and construct validity
To assess whether the measure could discriminate
between patients with varying levels of disease severity,
patients were categorized according to their level of
pulmonary impairment: mildly impaired group
(FEV1G71%pred), moderately impaired group (FEV1
41–70%pred) and severely impaired group
(FEV1F40%pred) w20x. In addition, patients were cat-
egorized according to their nutritional status: nourished
group (BMI G19) and malnourished group (BMI -
19).
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Table 1
CFQ-14q scores, Cronbach alpha and test–retest reliability for each
domain
CFQ score Alpha Test–retest
(mean"S.D.) coefficient reliability
Physical functioning 64.4"25.7 0.92 0.98
Vitality 56.3"17.6 0.81 0.90
Emotional state 77.7"15.6 0.69 0.84
Social functioning 63.1"24.8 0.64 0.97
Role limitations 60.6"27.2 0.74 0.98
Body image 68.7"21.2 0.45 0.89
Eating disturbances 78.0"22.9 0.66 0.87
Treatment constraints 61.7"22.3 0.53 0.83
Embarrassment 80.1"18.6 0.53 0.90
Respiratory constraints 53.0"13.4 0.79 0.92
Digestion 84.1"18.5 0.69 0.72
Weight 72.6"32.8  
Health problems 70.6"23.6 0.73 0.98
 is single item scale.
Since disease severity is related to older age compar-
isons were made between age groups: adolescents (14–
17 years), young adults (18–25 years) and adults (26
years of age and older). Comparisons were also made
between males and females.
Construct validity was assessed by correlating CFQ
scores with pulmonary functioning.
2.7. Pulmonary function
Forced vital capacity (FVC) and forced expiratory
volume in one second (FEV1) were obtained from
maximal expiratory flow–volume curves (Masterscreen;
Jaeger, Wuerzburg, Germany). Values are expressed as
the percent of predicted values w21,22x.
3. Statistical analyses
The Statistical Package for the Social Sciences (SPSS
for Windows version 10.1) was used for data manage-
ment and analyses. The internal consistency reliability
was evaluated using Cronbach’s a. Spearman (rs) cor-
relation coefficients were used to describe relationships
between outcome measures. Correlations were interpret-
ed as described by Guyatt and colleagues: less than 0.2
as very weak, from 0.2 to 0.35 as weak, from 0.35 to
0.5 as moderate, and 0.5 or greater as strong w23x.
Intraclass correlation coefficients were used to estimate
the reproducibility (test–retest reliability) w24x. Domain
comparisons between groups were made using t-tests
for unrelated samples and one-way analysis of variance
(ANOVA). Post hoc testing was done with Tukey’s
honest significant difference, which corrects for multiple
comparisons. Effect sizes (ES, i.e. the ratio of difference
in mean scores to the pooled baseline standard deviation
w25x were calculated to assess the relative magnitude of
observed differences. ES is interpreted using criteria
described by Cohen: 0.2 represents a small relevant
difference; 0.5 a moderate difference and differences of
0.8 or higher are interpreted as a large difference w26x.
Differences were considered significant if P-0.05 (two-
tailed). Data are presented as mean "S.D. unless
otherwise indicated.
4. Results
Eighty-four patients with CF (mean age: 21.4 years,
range 14.0–46.5 years) who had moderate to severe
airway obstruction (mean FEV1: 58.5%, range 15–
121%; mean FVC: 74.1%, range 26–121%) completed
the CFQ-14q. Table 1 shows mean values of the
different domains. The lowest scores on the CFQ-14q
were found for vitality and respiratory symptoms, while
the highest scores were found for digestion and
embarrassment.
4.1. Internal consistency
The internal consistency reliability levels (Cronbach
alpha) for the domains of the CFQ-14q are shown in
Table 1. Most domains had an acceptable Cronbach
alpha coefficient (0.60 or above). The exceptions to this
were body image, treatment burden and embarrassment.
Overall, items in the CFQ-14q loaded conceptually on
their respective domains with all of the loadings above
0.40.
4.2. Reproducibility
Twenty-one patients (22.8"8.9 years; range 13.9–
36.4 years) with moderate pulmonary dysfunction
(FEV1 62.1%"20.0%; range 29.2–87.0%) agreed to
participate in the test–retest reliability phase. The intra-
class correlation coefficients were high for all domains,
ranging from 0.72 to 0.98 (Table 1). This means that
the domain scores of the CFQ-14q are highly
reproducible.
4.3. Discriminative and construct validity
To assess whether the measure could differentiate
between patients with varying degrees of disease sever-
ity, patients were categorized according to the level of
pulmonary impairment (Table 2). Three groups were
formed: mildly impaired group (Ns28, FEV1
89.1%"14.0%), moderately impaired group (Ns36,
FEV1 56.0%"8.6%) and severely impaired group (Ns
20, FEV1 26.4%"7.1%). ANOVA tests indicated sig-
nificant main effects for physical functioning (Fs27.34,
P-0.001), body image (Fs13.43, P-0.001), eat dis-
turbances (Fs5.17, P-0.01), respiratory symptoms
(Fs5.78, P-0.01), health problems (Fs4.16, P-
0.015) and weight (Fs5.57, P-0.01). Table 3 shows
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Table 2
Comparison between CFQ-14q scores and disease severity
Mild CF Moderate CF Severe CF
(mean"S.D.) (mean"S.D.) (mean"S.D.)
Physical functioning 78.5"20.5 69.0"19.4 36.3"21.1
Vitality 58.9"19.4 55.2"16.2 54.6"17.6
Emotional state 79.8"19.7 77.2"12.1 75.7"15.3
Social functioning 66.4"24.3 60.6"26.7 62.9"22.5
Role limitations 66.0"27.4 54.9"26.8 65.3"27.0
Body image 81.0"19.1 67.9"17.6 52.8"19.7
Eating disturbances 88.7"19.8 73.6"22.3 70.8"23.4
Treatment burden 67.9"26.0 60.6"19.1 55.0"21.0
Embarrassment 83.3"17.5 71.0"20.7 80.8"18.3
Respiratory constraints 58.5"11.7 52.7"12.2 45.8"14.7
Digestion 81.5"18.3 81.9"21.2 91.7"10.1
Weight 88.1"22.6 67.6"33.3 60.0"36.8
Health problems 78.2"22.7 71.0"20.7 59.1"26.0
The scores range from 0 to 100 with higher scores corresponding to higher quality of life.
Table 3
Comparison between CFQ-14q scores and disease severity
Mild CF Mild CF Moderate CF
vs. moderate CF vs. severe CF vs. severe CF
d (95%CI)i d (95%CI)i d (95%CI)i
Physical functioning 9.6 (y2.5 to 21.7) 42.3 (28.3 to 56.4) 32.7 (19.3 to 46.2)
Vitality 3.8 (y6.9 to 14.4) 4.3 (y0.8 to 16.7) 0.6 (y11.2 to 12.4)
Emotional state 2.5 (y6.9 to 12.0) 4.1 (y6.9 to 15.1) 1.6 (y8.9 to 12.0)
Social functioning 5.7 (y9.3 to 20.8) 3.5 (y14.0 to 20.9) y2.3 (y18.9 to 14.4)
Role limitations 11.1 (y6.0 to 28.2) 0.7 (y22.0 to 23.5) y10.4 (y32.1 to 11.4)
Body image 13.1 (1.9 to 24.2) 28.2 (15.2 to 41.2) 15.1 (2.7 to 27.5)
Eating disturbances 15.1 (2.0 to 28.2) 17.9 (2.6 to 33.1) 2.7 (y11.7 to 17.3)
Treatment burden 7.2 (y6.1 to 20.5) 12.9 (y2.6 to 28.3) 5.6 (y9.1 to 20.4)
Embarrassment 6.2 (y5.1 to 17.4) 2.5 (y10.5 to 15.5) y3.7 (y16.1 to 8.8)
Respiratory constraints 6.8 (y1.1 to 14.7) 13.1 (4.0 to 22.2) 6.3 (y2.3 to 14.9)
Digestion y0.4 (y11.3 to 10.9) y10.1 (y22.8 to 2.6) y9.7 (y21.8 to 2.4)
Weight 20.5 (1.8 to 39.2) 28.1 (6.3 to 49.8) 7.6 (y13.1 to 28.3)
Health problems 7.3 (y6.3 to 20.9) 19.2 (3.3 to 35.0) 11.9 (y3.3 to 27.0)
d (95%)sdifference between means with 95% confidence interval. Significant interaction effects in bold.i
Table 4
Effect sizes between mild, moderate and severe CF for CFQ-14q domains
ES mild CF ES mild CF ES moderate CF
vs. moderate CF vs. severe CF vs. severe CF
Physical functioning 0.48 2.03 1.61
Vitality 0.21 0.23 0.04
Emotional state 0.16 0.23 0.11
Social functioning 0.23 0.15 y0.09
Role limitations 0.41 0.03 I0.39
Body image 0.71 1.45 0.81
Eating disturbances 0.72 0.83 0.12
Treatment burden 0.32 0.55 0.28
Embarrassment 0.64 0.14 I0.50
Respiratory constraints 0.49 0.96 0.51
Digestion y0.02 I0.69 I0.59
Weight 0.72 0.92 0.22
Health problems 0.33 0.78 0.51
ES: effect size. ES-benchmarks: 0.2 is a small relevant difference, 0.5 is a moderate difference and 0.8 is a large difference.
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Table 5
Correlation between CFQ-14q scores and pulmonary function
PF BI ED TB RC W HP
FEV %pred1 0.62*** 0.52*** 0.33** 0.26* 0.36** 0.40*** 0.34**
FVC% pred 0.58*** 0.41*** 0.24* – 0.23* 0.40*** 0.27*
PF: physical functioning; BI: body image; ED: eating disturbances;
TB: treatment burden; RC: respiratory constraints; W: weight; HP:
health problems; FEV : forced expiratory volume in one second;1
FVC: forced vital capacity. Only significant correlations are reported.
P-0.05, P-0.01, P-0.001.* ** ***
significant post-hoc comparisons between CFQ domains
and disease severity.
ES’s of the CFQ-14q are shown in Table 4. Most
domains showed at least a small relevant difference
between categories of pulmonary impairment (27 out of
39 comparisons).
With respect to nutritional status, comparisons
between the nourished (Ns41, BMI 26.6"2.1 kg m2)
and malnourished group (Ns43, BMI 17.7"1.0 kg
m2) demonstrated that the nourished group had higher
scores for body image (72.2"16.8 vs. 65.1"18.3, P-
0.05), eating disturbances (83.3"20.1 vs. 72.4"21.3,
P-0.05) and weight (77.5"21.3 vs. 67.1"22.1, P-
0.05).
Comparisons were made between adolescents (Ns
35; 15.4"1.1 years), young adults (Ns31; 20.5"1.4
years) and adults (Ns18; 34.5"6.3 years). ANOVA
tests indicated significant main effects for physical
functioning (Fs13.56, P-0.001), vitality (Fs4.44,
P-0.05), body image (Fs6.29, P-0.01), treatment
burden (Fs3.58, P-0.05), respiratory symptoms (Fs
9.87, P-0.01), health perceptions (Fs10.17, P-0.01).
Post hoc analyses revealed the following differences
between age groups: (1) adolescents reported higher
quality of life than young adults for the body image
domain; (2) adolescents reported higher quality of life
than adults for the domains of physical functioning,
vitality, body image, treatment burden, respiratory symp-
toms, digestion and health perception; (3) young adults
reported higher quality of life than adults for the
domains of physical functioning, vitality, respiratory
symptoms and health perception.
Comparisons between male (Ns44) and female (Ns
40) patients demonstrated that males had higher scores
for the emotional functioning domain (80.9"12.2 vs.
74.2"18.1, P-0.05) and lower scores for the body
image domain (62.9"24.3 vs. 75.0"15.0, P-0.01).
Table 5 shows weak to moderate correlations for
pulmonary function with treatment burden, health per-
ceptions, weight, eating disturbances, respiratory symp-
toms, and strong correlations with physical functioning,
and body image. The results indicated that patients with
worse pulmonary function reported poorer quality of life
on these domains.
5. Discussion
This study assesses the reliability and validity of the
Dutch version of a disease-specific measure of HRQOL
for adolescents and adults with CF (CFQ-14q). The
conceptual model of the CFQ was confirmed and the
internal consistency was acceptable for most domains.
Strong test–retest reliability was obtained and discrimi-
native validity with pulmonary function, nutritional stat-
us and age was demonstrated.
The homogeneity and the internal consistency relia-
bility estimates of the CFQ-14q were adequate. How-
ever, three domains showed a low Cronbach alpha
coefficient. Internal consistency coefficients of the treat-
ment burden domain have found to be even lower in
previous studies w27x. One possible reason for this is
that early detection of CF leads the initiation of treat-
ment regimens at a very young age. Patients may slowly
accommodate to deterioration in their health status and
a concomitant increase in the treatment regimen. There-
fore, they may not perceive this as limiting their daily
functioning. Internal consistency on the body image
domain was also poor. The low alpha coefficient was,
in part, caused by a gender effect. The Cronbach alpha
for males and females was 0.56 and 0.10, respectively.
However, deleting gender-based items or scales could
lead to losing important information related to males
and females with CF. For example, there is a significant
gender difference in morbidity and mortality among
males and females with CF which may be better under-
stood in relation to their HRQOL scores w28x. Recently,
revisions were made in the body image, treatment burden
and Embarrassment domains to improve validity. These
items will be tested in subsequent studies with the CFQ.
Currently, there is only one other validated CF-
specific HRQOL measure for adolescents and adults
(CFQoL) w20x. The authors reported high Cronbach
alpha coefficients on all domains. However, this measure
does not have a version for children with CF. After
evaluation of the Dutch child version, which is presently
underway, the CFQ questionnaires make it possible to
follow individual patients throughout their life span and
to capture the impact of the disease on the patient’s
ability to cope with various aspects of the illness.
Furthermore, there was no effort to counterbalance
positively and negatively worded items on the CFQoL,
which can skew the wording of the items in a negative
direction (‘CF makes it difficult for me to«’).
The analysis of test–retest reliability showed high
intraclass correlations, indicating that the assessment of
HRQOL is stable over a 10–14 day period. However,
the patients who participated in the test–retest reliability
phase were only moderately impaired which might have
effected the results. Further testing of the test–retest
reliability of the CFQ in patients with a greater variety
of respiratory impairment is, therefore indicated.
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The CFQ-14q questionnaire seems applicable to a
broad population of patients with CF since differences
in CFQ scores were not only found for all severity
groups (as measured by FEV1) but also for nourished
and malnourished patients. It is important to note that
the discriminative validity with respect to pulmonary
function only showed significant differences between
severity groups for six domains. However, the sample
size for this study was relatively small and in order to
account for the effect of sample size effect sizes were
calculated. Small effect sizes (-0.5) indicate that sta-
tistically significant outcome might be a function of
sample size. Stronger evidence of discriminative validity
might have been found in the vitality, social functioning,
emotional state and role limitations domains with a
larger sample size. However, CFQ scores on these
domains were clearly reduced. Although respiratory
involvement is of major importance because pulminary
disease is primarly responsible for morbidity and mor-
tality in patients with CF w1x, pulmonary function
measurements are possibly not sensitive enough to detect
differences on these domains between subgroups patients
with this multi-systemic disease.
Important differences were also found age and sex.
These findings converge with the results of other studies,
showing that gender differences exist in morbidity and
mortality with CF w28,29x. Clinicians should beware of
the fact that thinness and low body weight are perceived
by women as less of a problem than males w6x, although
this condition is unfavarouble for their health w30–32x.
Some issues in the present study need further com-
ment. Although the construct validity of the CFQ-14q
with pulmonary function is good, assessment of its
relationship to generic health status and psychological
well-being should be conducted. Data are also needed
on the responsiveness of the CFQ-14q, which measures
whether a questionnaire is able to detect changes brought
about by an intervention. However, a prerequisite of
sensitivity testing is the establishment of the reliability
and stability of the measure, which in this study, appears
to be very good. Evaluation of the child and parent
versions of the CFQ is presently underway.
Generic HRQOL and respiratory-specific question-
naires are unlikely to reflect adequately the symptoms
and areas of functioning that are relevant for majority
of patients with CF w5,33x. Incorporating disease-specific
HRQOL measurements with the CFQ-14q question-
naire in the care of patients may improve our understand-
ing of the impact of CF on the lives of these patients in
several ways. Firstly, it may be helpful in detecting
transient changes in health status caused by worsening
in pulmonary function or pulmonary exacerbations that
are both associated with deterioration in psychosocial
and physical functioning. Secondly, our understanding
of the basic pathophysiological mechanisms and signif-
icant improvements in diagnosis and treatment have
increased. These developments improved prognosis and
median survival. Recent estimates have projected a
median survival of 40 years for children born in 1990
who are receiving current standard therapy for CF
w34,35x. However, the quality of this improved survival
has not been assessed. The CFQ-14q can be used to
describe longitudinal changes as a function of deterio-
ration in disease status w20x. Changes on a psychosocial
level that take place over time may thereby supplement
traditional physiological measurements like pulmonary
function. Thirdly, the CFQ-14q may be useful in
understanding more clearly how clinical trials or specific
interventions (e.g. aerosol therapy, tube feeding) may
impact patient perceptions of HRQOL. Fourthly, the
CFQ-14q may improve communication between clini-
cians and patients by facilitating discussion on issues
that are of importance to patients. This enables clinicians
to focus more attention on patient’s individual percep-
tions of illness and prioritize problems by their impor-
tance to patients and thereby informing medical
decision-making. Moreover, patient’s perceptions of
improved functioning that are not reflected in conven-
tional medical outcomes may be an important factor in
promoting adherence to time-consuming and tedious
therapy w5x.
We conclude that the results show adequate validity
and reliability of the CFQ-14q questionnaire. This
measure holds promise for assessing HRQOL in multi-
center international studies.
Appendix A: List of items of the Dutch CFQ-14H
Domain Question Content of questions
Physical 1 Difficulty performing vigorous activities
such as running or sports
2 Difficulty to walk as fast as others
3 Difficulty carrying or lifting heavy
things such as books
4 Difficulty climbing one flight of stairs
5 Difficulty to climb stairs as fast as others
13 Difficulty walking
19 Trouble recovering after physical effort
20 Limit vigorous activities such as
running or sports
Vitality 6 Felt happy
9 Felt tired
10 Felt energetic
11 Felt exhausted
Emotional 7 Felt worried
state 8 Felt useless
12 Felt sad
28 Difficult to make plans for the future
33 Feel lonely
Social 22 Stayed at home more than you wanted
26 Feel comfortable sleeping away
from home«
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30 To get together with friends a lot
32 Feel comfortable going out at night
Role 37 Absent from school or work
because of illness or treatments
39 Trouble keeping up with school,
work or daily activities
Body image 23 Think you are too thin
24 Think you are physically different
from others your age
25 Feel bad about physical appearance
Eating 14 Feel about eating
21 Force myself to eat
Treatment 15 Treatment makes daily life more difficult
burden 16 Time spend on treatment each day
compared to one year ago
Embarrassment 27 People ask uncomfortable questions
29 People are afraid that my illness may
be contagious
31 Think coughing bothers others
Health 17 Health at this moment
18 Health compared to three months ago
34 Feel healthy
35 Lead a normal life
Weight 40 Trouble gaining weight
Respiratory 41 Felt congested
42 Coughing during the day
43 Cough up mucus
44 Color mucus
45 Wheezing
46 Trouble breathing
47 Woke up during the night because
of coughing
Digestion 48 Diarrhea
49 Abdominal pain
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